Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Prio Wealth Limited Partnership

Prio Wealth Limited Partnership trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,360 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the period. Prio Wealth Limited Partnership’s holdings in Gilead Sciences were worth $2,700,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in GILD. J. W. Coons Advisors LLC lifted its stake in Gilead Sciences by 2.8% during the fourth quarter. J. W. Coons Advisors LLC now owns 11,130 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 300 shares in the last quarter. Evoke Wealth LLC acquired a new position in Gilead Sciences during the fourth quarter worth $204,000. Rathbones Group PLC lifted its stake in Gilead Sciences by 3.7% during the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 150 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its stake in Gilead Sciences by 19.1% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 7,436 shares of the biopharmaceutical company’s stock worth $602,000 after purchasing an additional 1,195 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in Gilead Sciences by 55.9% during the fourth quarter. Jones Financial Companies Lllp now owns 1,447 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 519 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a research report on Monday, September 16th. Truist Financial upped their price objective on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Royal Bank of Canada upped their price objective on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research report on Wednesday, September 4th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $83.94 on Wednesday. The stock’s 50-day moving average is $78.53 and its two-hundred day moving average is $71.67. The firm has a market cap of $104.58 billion, a price-to-earnings ratio of 233.17, a PEG ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.